Comparison of the recovery quality between remimazolam and propofol after general anesthesia: systematic review and a meta-analysis of randomized controlled trials.


Journal

PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425

Informations de publication

Date de publication:
2024
Historique:
received: 30 04 2024
accepted: 25 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: epublish

Résumé

To evaluate the recovery quality between remimazolam and propofol after general anesthesia surgery. We included eligible randomized controlled trials (RCTs) in EMBASE, PubMed, Cochrane Central, Scopus, and Web of Science up to June 26, 2024 for comparison the recovery quality of remimazolam and propofol after general anaesthesia. The primary outcomes were the total Quality of Recovery-15 (QoR-15) and five dimensions of QoR-15 on postoperative day 1 (POD1). Secondary outcomes were adverse events, the Quality of Recovery-40 (QoR-40) on POD1, and the intraoperative and postoperative time characteristics. Thirteen RCTs with a total of 1,305 patients were included in this meta-analysis. Our statistical analysis showed that remimazolam group had higher QoR-15 score on POD1, with no significant difference (Mean Difference (MD) = 1.24; 95% confidence interval (CI), [-1.67-4.15]; I Our analysis showed that the recovery quality of the remimazolam group after general anaesthesia was similar to propofol group, while the incidence of adverse events was low in remimazolam group. As a potential anesthetic, remimazolam can be used in place of propofol for surgical general anesthesia.

Identifiants

pubmed: 39210920
doi: 10.7717/peerj.17930
pii: 17930
pmc: PMC11361258
doi:

Substances chimiques

Propofol YI7VU623SF
remimazolam 7V4A8U16MB
Benzodiazepines 12794-10-4
Anesthetics, Intravenous 0
Hypnotics and Sedatives 0

Types de publication

Journal Article Systematic Review Meta-Analysis Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e17930

Informations de copyright

©2024 Zhu et al.

Déclaration de conflit d'intérêts

The authors declare there are no competing interests.

Auteurs

Caiyun Zhu (C)

DepartmentofPharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
DepartmentofPharmacy, Zibo Integrated Traditional Chinese and Western Medicine Hospital, Zibo, China.

Ran Xie (R)

DepartmentofPharmacy, Zibo Integrated Traditional Chinese and Western Medicine Hospital, Zibo, China.

Fang Qin (F)

DepartmentofPharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
DepartmentofPharmacy, Liuzhou People's Hospital, Guangxi, China.

Naiguo Wang (N)

Department of Spinal Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.

Hui Tang (H)

DepartmentofPharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Stem Cell Clinical Institute, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH